Dr Mollie V. Willliams joins Ethics Talk to discuss her article, coauthored with Dr Olaitan Ajisafe: “How Should Exposure Risk to Tactical Personnel Be Balanced Against Clinical and Ethical Rescue Demand?”
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The high prevalence of violence experienced by Native American women and femme-identifying individuals requires clinicians and staff to better understand social determinants of violence.
AMA J Ethics. 2020;22(10):E888-892. doi:
10.1001/amajethics.2020.888.
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018;20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126
Jane Bartels, MBBS and Christopher J. Ryan, MBBS, MHL
When patients cannot give informed consent or refusal for antipsychotic medication, physicians must meet specific criteria to justify temporarily withholding a diagnosis.
AMA J Ethics. 2018;20(12):E1119-1125. doi:
10.1001/amajethics.2018.1119.
Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.